Analyst Ratings for Silver Standard Resources Inc. (SSRI)

Updated: 2017-07-27

Silver Standard Resources Inc. (NASDAQ:SSRI) was awarded an average rating of Overweight from investment analysts following the stock. About 30 days ago, SSRI was issued an average rating of Overweight.

Of the 10 analysts covering the stock, 5 gave it a buy rating, 1 issued an overweight rating, 4 issued a hold rating, 0 issued an underweight rating, and 0 issued a sell rating. Over the past 90 days, the number of analysts that are bullish on the stock has increased by 1. During this time, the number of analysts bearish on the stock has increased by 0.

Many analysts weighed in on price targets for SSRI. The maximum price target given was 17.26, implying potential capital gains of 80.53 percent. The most pessimistic analyst gave a price target of 10.56, implying potential capital losses of 10.45 percent. It is crucial to not blindly accept any price targets or stock ratings, because many analysts have it in their best interest to give positive coverage of certain stocks.

In the last 30 days, analysts have changed their quarterly earnings estimates downwards by an average of -0.89 percent. This can be compared with the average change in earnings estimates over the past 3 months, which is 0 percent. On the other hand, earnings estimates for the fiscal year have been revised downwards by -12.57 percent, as compared to a month ago. If we look at the last 90 days instead, we find a net average change of 0 percent in FY estimates.

Investors like to see analysts making revisions in the same direction, as that raises confidence in the revisions. 0 analysts made positive revisions to their quarterly estimates over the past month, while 2 analysts made negative revisions. During this time, 0 analysts made positive revisions in their estimates for this fiscal year's earnings, while 2 analysts decreased their estimates.

The growth rate of SSRI's earnings is estimated by analysts to be -53.99 percent. Another measure frequently examined by investors is the PEG ratio. Smaller PEG ratios are desirable, because people typically see that as an indicator of higher growth relative to stock price. Wall Street investors typically prefer a PEG ratio to be smaller than 1, though it could be better to see where the ratio stands relative to peers in the industry. The PEG ratio of SSRI is -0.27.

In the last 52-weeks, SSRI has achieved a high of 15.84 and a low of 7.70. The current market price is above the trailing year's low by 24.17 percent, and 39.64 percent lower than its 52-week high. SSRI has a price/earnings ratio of 14.59. Investors typically compare the P/E ratio to a company's peers in the industry. The SSRI value stock report compares SSRI to some of its peers using value stock charts. The market cap of SSRI is $1.17 billion. SSRI's next earnings release will be on 0000-00-00, which is days away.